FDA approves Akynzeo to prevent chemotherapy-induced nausea and vomiting

the ONA take:

The U.S. Food and Drug Administration (FDA) has approved Akynzeo, a combination product of netupitant and palonosetron, for the treatment chemotherapy-induced nausea and vomiting (CINV) in patients with cancer.

Akynzeo will be available as a fixed combination capsule made up of the two drugs. Palonosetron, a 5-HT3 antagonist, is available as a single agent both intravenously and orally. The intravenous formulation is effective for both acute and delayed CINV; however, the oral formulation is only approved for the treatment of acute CINV. Netupitant, a novel highly selective neurokinin 1 (NK1) receptor antagonist from the same class of drugs as aprepitant, prevents both acute and delayed phase CINV.

Two clinical trials consisting of 1,720 patients with cancer receiving chemotherapy established the effectiveness of Akynzeo. The first study showed that 98.5% of patients receiving Akynzeo did not experience acute CINV, 90.4% did not experience delayed CINV, and 89.6% did not experience overall CINV after the start of cancer chemotherapy.

Patients taking oral palonosetron only experienced higher incidences of CINV. The second study demonstrated similar results. Adverse effects observed with Akynzeo were headache, asthenia, fatigue, dyspepsia, and constipation.

FDA approves Akynzeo to prevent chemotherapy-induced nausea and vomiting
Akynzeo approved for the treatment chemotherapy-induced nausea and vomiting.

The U.S. Food and Drug Administration has approved Akynzeo (netupitant and palonosetron) to treat nausea and vomiting in patients undergoing cancer chemotherapy. Akynzeo is a fixed combination capsule comprised of two drugs. Oral palonosetron, approved in 2008, prevents nausea and vomiting during the acute phase (within the first 24 hours) after the start of cancer chemotherapy.

Netupitant, a new drug, prevents nausea and vomiting during both the acute phase and delayed phase (from 25 to 120 hours) after the start of cancer chemotherapy.

READ FULL ARTICLE From Medical News Today
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs